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Objectives: The rapid increase in drug expenditure has become a major source of public criticism in China. In 2009,
the National Essential Medicine System (NEMS) was launched in China to control drug prices and improve access to
medicines. This study investigated whether and to what extent the prices of essential medicines were reduced after
the introduction of NEMS.
Methods: Data were obtained from 149 public primary healthcare centers (PHCs) in four Chinese provinces
(Shandong, Zhejiang, Anhui and Ningxia) using a facility-based survey. In total, 10,988 essential medicines were
investigated. Individual price differences and a price index were used to measure price changes for three different
lists: 2009–2010, 2010–2011, and 2009–2011.
Results: In the comparison between 2009 and 2010, a median decrease of 34.4% [95% confidence interval:
30.4%–39.1%] was observed in drug prices and the number of drug sales increased by 1.5%. The higher the retail
price in 2010, the more the drug sales increased compared with 2009 (χ2 = 75.9, p < 0.01). The drug revenues in 100
of the 149 surveyed PHCs decreased by an average of 39%. Where the available data allowed price changes for
2009–2011 to be assessed, drug prices were reduced significantly in 2010, but a modest decrease was seen in 2011.
The Laspeyres index was less than 100 and the Paasche index was larger than the Laspeyres index in 2010 and
2011, which indicated that the frequently prescribed drugs usually had higher prices and any price reduction was
milder.
Conclusions: The introduction of NEMS in PHCs in China led to price reductions in essential medicines. However,
more-expensive drugs were preferred in the postreform period. Most PHCs had less drug revenue and could en-
counter financing dilemmas after the implementation of NEMS. Policy options such as improving the compensation
mechanism and rational use of drugs should be further promoted in PHCs.
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The rapid increase in drug expenditure has become a
critical obstacle in accessing health care for the poor and
its control is a key objective for healthcare policy makers
[1]. China is no exception. There are many reasons for
this increased expenditure on drugs. Reasonable factors
include more people being treated, more elderly people
needing more drugs, increased chronic diseases, and the* Correspondence: bianying@umac.mo
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unless otherwise stated.diffusion of new drugs. In 2010, the number of Chinese
aged 60 years and older reached 177 million, which
includes 13.3% of the residents of mainland China. This
is an increase of 2.9% compared with the same age
group in 2000 [2]. The latest National Health Services
Survey in China revealed that approximately 20% of the
Chinese population had chronic diseases in 2008, which
was an annual average of ten million new cases over the
last decade [3]. Most potentially irrational factors of in-
creased drug expenditure in China relate to the inflation
of drug prices, the increased volume of prescriptions,
and the induced demand for physicians to use moretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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enue has become an essential financial resource for most
public healthcare facilities, especially at primary health-
care centers (PHCs) (ranging from 50% to 90% of total
revenue) [6]. In contrast to most Western countries, the
healthcare provider is the main supplier of pharmaceut-
ical products in China, accounting for 70% of all drugs
sold and distributed [7]. The government set prices for
basic healthcare below actual cost to keep health care
affordable, but allowed a 15% profit margin on drugs to
ensure that healthcare facilities survive financially [8].
However, this price-setting approach induced an increase
in consumption and overuse of the more expensive or
profitable drugs [9].
As such, drug expenditures have been growing by 15%
per year and represent almost 50% of total healthcare
spending in China, compared with 18% in Organization
for Economic Cooperation and Development countries
[10]. This disparity is partly because of the 15% drug
markup policy (the supplier-induced drug expenditures
accounted for 12% to 37% of total medical expenditures)
and the severity of irrational use of drugs (nearly 80% of
randomly selected prescriptions were for unnecessary
antibiotics) [6].
In addition, China’s pharmaceutical distribution industry
is extremely fragmented with over 13,000 distributors in
2009. The three largest Chinese distributors accounted for
only 22% of the market in 2010 [11]. As a result of this
fragmentation, drugs are distributed through several layers
of distributors with multiple handoffs before reaching the
end-customer, which creates inefficiencies and higher
distribution costs in China. Furthermore, most pharma-
ceutical manufacturers have actively promoted their
products using a variety of strategies including hiring
numerous salespersons, sending medical representatives
to promote prescriptions, or advertising in public media
for over-the-counter products. These commercial promo-
tion activities and profits from multiple layers of distribu-
tion contribute to a substantial proportion of the total
costs of drugs [12].
Chinese households devoted 40%–60% of their out-
of-pocket healthcare expenditures to drugs between
1995 and 2008 according to the Chinese Health Statistical
Digest [13]. Therefore, the cost of serious illness is a major
financial burden for families at the household level. To
alleviate Chinese citizens’ burden of expensive medical
bills and increase their access to essential medicines, in
April 2009 the State Council of China launched the
National Essential Medicine System (NEMS) with the goals
of cutting the profit link between healthcare facilities, doc-
tors, and drugs, and to improve drug availability, afford-
ability, and rational use [14]. NEMS was initially designed
for public primary healthcare facilities, with the intention
of extending it to private providers and hospitals.The NEMS included policies targeting drug selection,
production, procurement, distribution, pricing, use and
reimbursement. The core of the program was the National
Essential Medicine List, which included 205 Western
medicines and 102 traditional Chinese medicines (TCMs)
[15]. To address local needs, the central government gave
authority to provincial governments to supplement the list
according to their economic situation and specific needs.
Another key policy element of the NEMS was a zero
markup policy under which essential medicines were sold
to patients at the procurement price, with no profit to
healthcare facilities for the sale. Province-based bidding
and centralized procurement for essential medicines were
developed to simplify the supply chain and strengthen
market competition, which were effective in achieving the
lowest possible drug prices.
The NEMS has been accepted worldwide as a powerful
tool to promote access and rational use of quality drugs.
There is substantial evidence that the adoption of the es-
sential medicines concept has contributed to better cost-
effectiveness in healthcare systems [16,17]. This study
was to investigate the impact of NEMS on drug prices
and to determine whether and to what extent the prices
of essential medicines were reduced after the introduc-
tion of NEMS.
Methods
Study design and sampling
This was a comparative study of pre- and postreform
periods in China. The data were collected from 2009 for
the prereform period and from 2010 and 2011 for the
postreform period. A field survey was conducted to
collect the price information of essential medicines.
Four Chinese provinces, Shandong, Zhejiang, Anhui,
and Ningxia, which represented varying levels of socioeco-
nomic status, were selected as research areas. Shandong
and Zhejiang are located in eastern China and represent
the developed parts of China. Anhui is part of central
China and is an example of a moderately developed re-
gion. Ningxia is in northwest China and is an undevel-
oped region. One hundred and forty-six public PHCs
were included through stratified sampling in these four
provinces.
The survey in Zhejiang and Anhui was conducted in
2010. It was based on the program “Mid-term Evaluation
on Implementation Effects of National Essential Medicine
System,” organized by the National Development Reform
Committee, China. In each PHC, drugs used in August
2009 and August 2010 with the same strengths and
dosage forms were included for price comparison. The
surveys in Shandong and Ningxia were conducted in
2011. In each PHC, price comparisons were made for
drugs used in June 2009, June 2010, and June 2011 with
the same strengths and dosage forms.
Song et al. Journal of Pharmaceutical Policy and Practice 2014, 7:12 Page 3 of 8
http://www.joppp.org/content/7/1/12Data collection
A self-compiled questionnaire was used collect price
information in the information or purchasing divisions
of the PHC. Items included drug name, dosage, form,
price, and sales. All the information in 2009, 2010, and
2011 were acquired through the PHCs’ drug-price re-
cording system. The completed forms were checked on a
daily basis. A follow-up telephone call was placed if any
important information was missing.
Data analysis
Drugs (same chemical entity) with various strengths and
dosage forms were considered as separate drugs in this
study. For example, enalapril tablet 10 mg and enalapril
tablet 5 mg were considered as two drugs. All compared
drugs were the same generic name (and not necessarily
from the same producers). The number of drug sales
was calculated in accordance with the drug packaging
units. For example, norfloxacin’s capsule specification
was 0.1 g per tablet, packaging 12 tablets per board, and
its sales were calculated in line with boards. In total,
10,988 drugs were analyzed in this research, which in-
cluded 7769 national essential medicines (NEDs) and
3220 provincial supplemented essential medicines (PEDs).
During the analysis, the consumer price index was used to
correct 2010 and 2011 prices to 2009 prices to account for
deflation. Additionally, all prices were converted to United
States dollars (US$) using the mean exchange rate for the
year 2009, which was 6.8 Chinese yuan to one US$.
Individual price differences
Individual price differences were calculated for each
drug before and after NEMS. The comparison was per-
formed as the percentage difference that may appear as a
negative or positive value. Compared with the drug price
in period 1, the percentage change in drug price in period
2 was calculated using formula (1). Similarly, the percent-





Q% ¼ Q2‐Q1ð Þ
Q1
 100% ð2Þ
Next, the magnitude of the overall price change was
calculated for three different lists: 2009–2010, 2010–2011,
and 2009–2011. Because individual price differences were
abnormally distributed, a median value was used in
discussing them. The 95% confidence interval (CI) of the
median value was also calculated. A nonparametric test
was used to compare price differences between the two
periods. A Pearson correlation test was used to test for
significant or nonsignificant variations in relationshipsbetween prices and sales. The statistical tests were per-
formed with IBM SPSS Statistics software (version
19.0, IBM SPSS, Armonk, NY, USA).
Price index
Economic theory defines a price index as reflecting what
happens to the overall level of prices in a given period of
time. A price with a fixed basket of goods is called a Las-
peyres index (PLa) in the economics literature, and a price
index with a changing basket is called a Paasche index
(PPa) [18]. During a relatively short period (e.g., 10 years),
a fixed basket of goods will not change. However, with
variation in consumer preferences and social production
capacities, the commonly used basket of goods will
change. Therefore the application of PLa and PPa can indi-
cate the interactive relationship between prices and sales.
In this study, all surveyed drugs were regarded as a fixed
basket, and each year the drugs ranked in the top 50 ac-
cording to the number of sales were regarded as a com-
monly used basket. These two indicators were calculated

















where P1i and P2i stand for prices of drug i in periods
1 and 2, and Q1i and Q2i stand for the use of drug i in
periods 1 and 2. For each price index, a value of less
than 100 means that the prices were reduced in a given
period of time, and a value of more than 100 means that
prices increased in a given period of time.
Results
Changes in drug prices
Individual price differences
In the comparison between 2009 and 2010, out of 10,988
surveyed drugs, the prices of 9747 (88.7%) drugs were
reduced by 39.8% (95% CI, 38.8%–40.0%) and 1057 (9.6%)
drugs were increased by 27.5% (95% CI, 25.0%–32.4%).
Overall, a median decrease of 34.4% (95% CI, 30.4%–
39.1%) was observed in drug prices compared with 2009.
The prices of NEDs were down by 35.3% and the prices of
PEDs decreased by 32.9%. In each province studied, drug
prices showed obvious decreases between 2009 and 2010
with statistical significance (p < 0.01). Details are presented
in Table 1. Tables 2 and 3 depict the price changes in
Table 1 Overall price differences for all drugs and for drugs in various subcategories (2009–2010)
Category N Price (in Chinese yuan) Price
chang (%)2009 2010 p-value
Category(1) Western medicines 7897 4.5 2.1 <0.01 −41.6
TCMs 3091 10.8 8.1 <0.01 −24.3
Category(2) NEDs 7768 5.0 2.6 <0.01 −35.3
PEDs 3220 9.0 5.5 <0.01 −32.9
Region Shandong 7897 3.5 1.9 <0.01 −40.0
Zhejiang 3091 7.4 4.1 <0.01 −33.6
Anhui 7768 5.0 2.2 <0.01 −37.0
Ningxia 3220 2.6 2.4 <0.01 −4.8
Total 10988 5.7 3.0 <0.01 −34.4
Note: United States dollar = 6.8 Chinese yuan.
p value refers to nonparametric test for statistical difference of prices between the two periods.
TCMs, traditional Chinese medicines; NEDs, national essential drugs; PEDs, provincial essential drugs.
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Pharmacology Classification from 2009 to 2010. Cardio-
vascular medicines, which have the second largest market
share after antimicrobial medicines in China, decreased by
28.3% in 2010 compared with their prices in 2009. The
price decrease was lower than the average level (34.4%)Table 2 Price changes of Western medicines categorized
according to Clinical Pharmacology Classification
(2009–2010)
Clinical pharmacology classification N Price
change (%)
Antiallergics 121 −60.3
Blood-related medicine 317 −52.6
Water-Electrolyte-Acid–base-Balance Medicine 842 −49.2
Antiparasitics 218 −48.9
Urinary system medicine 152 −48.8
Antimicrobial medicine 1643 −46.9
Gynecological medicine 94 −46.7
Vitamin & mineral supplements 519 −43.6
Antipsychotics 70 −42.3
Ophthalmic medicine 177 −40.0
Dermatologic medicine 291 −39.5
Nervous system medicine 298 −39.1
Digestive system medicine 842 −38.9
Respiratory system medicine 333 −37.5
Hormone 489 −34.8




Cardiovascular system medicine 805 −28.3
Biological medicine 72 72.2
Others 151 −50.0and ranked second to last. Antimicrobial medicines de-
creased by 46.9% in the corresponding period.
Trends in drug sales as prices changed
Compared with 2009, the number of drug sales in-
creased by 1.5% (95% CI, 0.0%–12.5%) in 2010 following
reductions in drug prices. Price reductions of 40% or
more increased the drug sales by about 5.3%. A 20%–40%
decrease in price was followed by an increase in drug sales
of 4.8%. Price reductions of less than 20% did not have an
impact on drug sales. Although the increased sales follow-
ing the reductions in drug prices were not substantial,
they still demonstrated a positive relationship between
them (χ2 = 96.1, p < 0.01). Furthermore, the higher the re-
tail price in 2010, the more the sales increased compared
with 2009 (χ2 = 75.9, p < 0.01) (Table 4). Table 4 shows
that the price decreases were relatively low for high-priced
drugs. For example, a decrease of 51.8% was observed in
the prices of drugs retailing for less than 2yuan (0.3US$),
while a fall of 16.3% was observed in the prices of drugs
retailing at more than 20yuan (2.9US$). Additionally, drug
revenues in 100 of 149 surveyed PHCs reduced by an
average of 39% in 2010 compared with the prereform
period.Table 3 Price changes of traditional Chinese medicines
categorized according to Clinical Pharmacology
Classification (2009–2010)
Clinical pharmacology classification N Price change (%)
Ophthalmic medicine 62 −35.4
Internal medicine 2309 −25.6
Surgical medicine 199 −25.5
Gynecological medicine 159 −24.2
Orthopedic medicine 288 −11.6
Ear, nose, and throat medicine 74 7.4
Table 4 Changes in the prices and sales for drugs of different price levels (2009–2010)
2010 price (in Chinese yuan) N Changes in the prices (%) Changes in the sales (%) p-value
0- 4189 −51.8 0 <0.01
2- 4420 −32.4 0.1
10- 1404 −23.6 15.6
20- 975 −16.3 20.5
Note: United States dollar = 6.8 Chinese yuan.
p value refers to Pearson correlation test for significant or nonsignificant variations in relationships between price levels and increased sales.
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The price trends of essential medicines in 2011 were in-
vestigated further in Shandong and Ningxia. As shown
in Figure 1, the results of this additional investigation
found that drug prices decreased each year after the im-
plementation of the NEMS (p < 0.01). In most cases,
drug prices showed a very large decrease in 2010 and a
modest decrease in 2011. In total, a decrease of 40%
(95% CI, 34.3%–43.7%) was observed in drug prices
between 2009 and 2011. The prices of TCMs and Western
medicines showed similar decreasing trends during this
period (p < 0.01). The drug revenues in PHCs showed a
continuous decline from 2009 to 2011 with statistical sig-
nificance (p < 0.05).
Analysis based on price index
Figure 2 shows the values of PLa and PPa for essential
medicines in the four Chinese provinces studied in 2010.
In each province, the value of PLa was less than 100 and
showed a decrease in drug prices. The value of PPa was
always larger than PLa in any condition, which indicated
that frequently prescribed drugs usually had higher price
levels with milder price reductions. Notably, the values
of PPa in Zhejiang and Ningxia reached as high as 116
in 2010 and showed a rise of 16% in the frequently pre-
scribed drug prices compared with 2009. The same





















Figure 1 Evolution of drug prices in Shandong and Ningxia in 2009–2Discussion
NEMS and changes of drug prices
This study compared the drug prices before and after
the implementation of NEMS in four Chinese provinces.
The results from the four provinces indicated a median
decrease of 34.4% in drug prices in 2010 compared with
2009. Further investigation in Shandong and Ningxia
showed that prices continued to drop in 2011. These
results are consistent with other research [19,20]. The
Chinese Ministry of Health reported that drug prices in
PHCs went down by about 38% in 2010 based on their
monitoring data from 13 provinces. Their report also
revealed that the drug prices in PHCs were lower than
in retail drug stores [19]. Another survey in Haikou,
Hainan province showed that drug prices decreased by
28.2% in 2012 compared with the same period before
2009 in six pilot PHCs [20]. Therefore, China’s NEMS
has a positive effect on the control of drug prices. Con-
siderable variation in price change was observed in the
four provinces studied, which reflected differences in
regulatory, economic, and administrative contexts. The
major contributing factors reported by previous studies
are centralized procurement and zero markup policy,
which are two key elements of the NEMS. Centralized
procurement helps to reduce the purchasing prices be-
cause suppliers are competing for government contracts,
and the zero markup policy cancels the profit margins























Paasche Index Laspeyres Index
Figure 2 Laspeyres index and Paasche index in the four
provinces studied in 2010.
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ber of successful examples at the global level. One is the
Eastern Caribbean Drug Service, which was established
to manage bulk purchasing and competitive tendering
on behalf of the member countries of the Organization
of Eastern Caribbean States. This service achieved an
average of 44% reduction in price during their first tender
cycle [24].
One of the most important objectives of NEMS is to

































Laspeyres index Paasche index
Ningxia
Figure 3 Laspeyres index and Paasche index in Shandong and
Ningxia in 2009–2011.that the lower prices are better. An excessive pursuit of
lower prices might increase the following risks: a) drugs
disappearing from the market because the price was too
low, which discourages manufacturers and distributors
from supplying the drugs; and b) potential quality risks
because the manufacturers may adulterate the drug
quality to ensure their profit margin is healthy. A report
from three Chinese provinces (Ningxia, Chongqing, and
Tianjin) showed that many county officials complained
that some manufacturers became reluctant to produce
certain drugs because the price controls and recom-
mended procurement procedures in the NEMS severely
curtailed their profit margin [23].
Expensive drugs tended to be more frequently used in
the postreform period
The price index expressed price changes in a different
way by indicating a price decrease in essential medicines
following the implementation of NEMS. Moreover, the
difference between PPa and PLa showed that the fre-
quently used drugs always had higher prices and milder
price reductions in the postreform period. This observa-
tion is consistent with the results based on the analysis
of individual price differences analysis (Table 4). Similar
findings were also reported in another survey in Shan-
dong [25]. The assumption of the NEMS policy design is
that drug consumers would prefer drugs to be cheaper.
However, this does not consider that drug prescriptions
are written by doctors, not by the paying patients. The
underlying motivation of doctors to use more-expensive
drugs may include: 1) the allocation of government subsid-
ies in many regions (i.e. Anhui, Ningxia) was based on pre-
scription volumes and represented only the lost profit
markup. In this case, the irrational incentives for generating
revenues from drugs were the same as prereform. 2) The fi-
nancial incentives given by the manufacturers to healthcare
facilities and doctors might have influenced their prescrib-
ing behaviors [26]. 3) The profit margin for expensive drugs
was relatively higher, which could encourage distributors to
guarantee their supply. Because of the lack of stock or the
unresponsive supply of lower-priced drugs, doctors had to
prescribe the more-expensive drugs.
PHCs’ financing dilemma
Most PHCs received less revenue from drug prescrip-
tions in the postreform period. In China, drug revenue
was the principle source of income for PHCs because
the medical revenue cannot support the full operational
costs of a PHC. Some PHCs encountered financing di-
lemmas after the implementation of NEMS. A survey in a
city in Zhejiang province performed by the Chinese Acad-
emy of Social Sciences showed that the total drug revenue
of all PHCs was 186 million yuan in 2009, which included
94 million yuan in profits. The total medical revenue was
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government funding was 20.4 million yuan. Therefore,
the available net revenue was 162 million yuan in 2009.
The salary of health personnel, which is the largest ex-
penditure of PHCs, was 114 million yuan a year. After
NEMS, these PHCs experienced financial deficits [27].
A survey in Zhenjiang in Jiangsu province found that 11
of all 13 PHCs experienced a financial deficit in 2011,
despite an increase in government funding compared
with the prereform period [28]. Furthermore, an investi-
gation in 12 PHCs of Shanghai, Sichuan, and Chongqing
indicated the average loss rate of the surveyed PHCs
was 5.7% in 2011, which showed an increase of more
than four times compared with 1.1% in 2009 [29]. There-
fore, there is an acute need to establish a scientific, ra-
tional, institutionalized, and standardized compensation
system for PHCs. Insufficient compensation may result in
shortages in routine operational activities, a weakened
ability to maintain their essential medicine system, or sales
of diagnostics, technologies, or other revenue-generation
methods to cover their basic operational costs [30].Limitations
The results of this study should be interpreted in light of
several limitations. The present study was conducted
shortly after China introduced NEMS. NEMS’s effective-
ness and impacts have not yet been fully realized. Fur-
thermore, reforms were still evolving during this study,
which means that the timeliness of this study also needs
to be updated. In addition, the results of this study were
based only on four selected provinces. Although these
four provinces were selected to explore different socio-
economic development levels, the conclusions of this
study should be cautiously generalized to China. There-
fore, there is still room for improvement in updating data,
choice of scale, variables, and research method. Countries
or other locations can use any indicators in the present
study as a baseline assessment for follow-up studies.Conclusions
The implementation of NEMS was found to have a positive
impact on drug prices in China. However, more-expensive
drugs were preferred because of irrational incentives in the
postreform period. Furthermore, most PHCs received less
revenue from drugs and may experience financing di-
lemmas after the implementation of NEMS. Policy options
such as improvement of the compensation mechanism and
rational use of drugs should be promoted further.
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